Stockreport

Roche receives FDA approval for first diagnostic tests to identify HER2-positive metastatic breast cancer patients eligible for ENHERTU [Yahoo! Finance]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF Roche's PATHWAY HER2 (4B5) test is the only test approved to identify all levels of HER2 expression. Roche's breast cancer diagnostic portfolio now provides clinician [Read more]